New diabetes drug tested in kidney patients: hope or hype?

NCT ID NCT01512849

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested an experimental diabetes drug called TA-7284 in 24 people with type 2 diabetes, some with normal kidneys and some with moderate kidney impairment. Researchers measured how the drug moves through the body, how it affects blood sugar, and whether it is safe. The goal is to understand if the drug works differently in patients with kidney problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TA-7284 (an experimental drug for type 2 diabetes)
What this could lead to: If successful, this could help determine the right dose of TA-7284 for diabetic patients with kidney problems, potentially leading to better blood sugar control.
What could go wrong: This is a very early Phase 1 study with only 24 participants, so results may not apply broadly. The drug may not work as expected or could cause side effects, especially in patients with kidney impairment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney failure type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Reserch site

Kanto, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.